Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNBELIEVABLE: Legend biotech | History Defined

Legend Biotech Conference Spotlights CARVYKTI’s Curative Potential, Earlier Use

Legend Biotech (NASDAQ:LEGN) used an investor and analyst event to highlight long-term data and physician perspectives supporting broader use of CARVYKTI, its BCMA-directed CAR T-cell therapy for multiple myeloma developed, manufactured and co-promoted with Johnson & Johnson. Chief Executive Of

MarketBeat · Jun 1

Legend Biotech Q1 Earnings Call Highlights

Legend Biotech (NASDAQ:LEGN) reported sharply higher first-quarter 2026 sales for CARVYKTI, its CAR T therapy for multiple myeloma, as management said demand continued to move into earlier lines of treatment and international markets expanded. Chief Executive Officer Ying Huang said the company beg

MarketBeat · May 12

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022

Upgrades

Benzinga · Nov 1, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · May 26, 2022

Analyst Ratings For Legend Biotech

Analysts have provided the following ratings for Legend Biotech (NASDAQ:LEGN) within the last quarter:

Benzinga · Mar 15, 2022

GenScript Losses Widen, But Investors Focus on Newly Approved Cancer Treatment

Key takeaways: GenScript Biotech said it lost up to $519 million last year, with its Legend Biotech unit accounting for nearly 70% of that Legend Biotech’s Cilta-cel CAR-T cell therapy product was approved by the FDA on Monday, and could become a major cash cow for GenScript Biotech By Molly…

Benzinga · Mar 1, 2022

The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Mar 1, 2022

Read news from The Economist, FT, and more,
with one subscription

FDA Approves JNJ-Legend Biotech Partnered Blood Cancer Therapy

The

Benzinga · Mar 1, 2022

FDA Slams Brakes On Legend Biotech's CAR-T Therapy Trial In Lymphoma Patients

The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ:

Benzinga · Feb 15, 2022

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.